{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06450639",
            "orgStudyIdInfo": {
                "id": "BN45398"
            },
            "organization": {
                "fullName": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            },
            "briefTitle": "An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy",
            "officialTitle": "A Phase II Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Pediatric Patients With Duchenne Muscular Dystrophy (SHIELD DMD)",
            "acronym": "SHIELD DMD",
            "therapeuticArea": [
                "Other"
            ],
            "study": "an-open-label-study-to-assess-the-efficacy-and-safety-of-satralizumab-in-duchenne-muscular-dystrophy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-09-30",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-05",
            "studyFirstSubmitQcDate": "2024-06-05",
            "studyFirstPostDateStruct": {
                "date": "2024-06-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy (DMD) age \u2265 8 to \\< 16 years old receiving corticosteroid therapy.",
            "detailedDescription": "Participants will be included in two groups: those presenting with fractures at baseline and those that are fracture naive at baseline.\n\nThe study will assess the potential of satralizumab to improve bone fragility and to increase muscle function.\n\nA weight tier based dose of satralizumab will be given by subcutaneous injection every 4 weeks"
        },
        "conditionsModule": {
            "conditions": [
                "Duchenne Muscular Dystrophy"
            ],
            "keywords": [
                "DMD, IL6, IL6R, bone, muscle, fractures, BMD, inflammation"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Satralizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive Satralizumab subcutaneous (SC) injection at a dose of 60 mg or 120 mg on Day 1 and Weeks 2 and 4 and then every 4 weeks (Q4W) from Weeks 8 to 104 (maintenance doses) until the study completion visit.",
                    "interventionNames": [
                        "Drug: Satralizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Satralizumab",
                    "description": "Satralizumab will be adminsitered SC in the abdominal or femoral region at a dose of 60 mg (participants weighing below 40 kg) or 120 mg (participants weighing more than or equal to 40 kg and less than or equal to 100 kg) on Day 1 and Weeks 2 and 4 (loading doses) and then Q4W from Weeks 8 to 104 (maintenance doses) until the study completion visit.",
                    "armGroupLabels": [
                        "Satralizumab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change from Baseline to Week 52 in Lumbar Spine (LS) Bone Mineral Density (BMD) Z-Score Measured By Dual-Energy X-ray Absorptiometry (DEXA)",
                    "description": "BMD of the LS is measured using DEXA",
                    "timeFrame": "Baseline to Week 52"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percentage of Participants with Treatment-Emergent Adverse Events",
                    "description": "An adverse event is any untoward medical occurrence in a patient or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment",
                    "timeFrame": "Up to approximately 30 Months"
                },
                {
                    "measure": "Percentage of Participants with Serious Adverse Events",
                    "description": "A serious adverse event is defined as any untoward medical occurrence that, at any dose: Results in death, Is life threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability or incapacity, Is a congenital anomaly or birth defect, Medically Significant",
                    "timeFrame": "Up to approximately 30 Months"
                },
                {
                    "measure": "Percentage of Participants with Adverse Events of Special Interest",
                    "timeFrame": "Up to approximately 30 Months"
                },
                {
                    "measure": "Change from Baseline to Weeks 24 and 52 in LS BMD Z-Score Measured by DEXA",
                    "timeFrame": "Baseline to Week 24 and Week 52"
                },
                {
                    "measure": "Change from Baseline to Weeks 24 and 52 in Total Body Less Head Bone Mineral Density (TBLH BMD) Z-Score Measured by DEXA",
                    "timeFrame": "Baseline to Week 24 and Week 52"
                },
                {
                    "measure": "Change from Baseline to Weeks 24 and 52 in Circulating Bone Metabolism Biomarkers",
                    "description": "Bone biomarkers are produced from the bone remodeling process and include bone formation biomarkers, bone resorption biomarkers and regulators of bone turnover",
                    "timeFrame": "Baseline to Week 24 and Week 52"
                },
                {
                    "measure": "Mean Number Per Participants of New Low-Trauma Long-Bone or Vertebral Fractures (VF)",
                    "description": "\"A low-trauma fracture is defined as one occurring spontaneously or resulting from a fall from a standing height or less, without major trauma or the influence of an external force (e.g. motor vehicle accident)\"",
                    "timeFrame": "Baseline, Week 52 and Week 104"
                },
                {
                    "measure": "Percentage of Participants with New Low-Trauma Long-Bone or VF",
                    "timeFrame": "Baseline, Week 52 and Week 104"
                },
                {
                    "measure": "Change in Time to Rise From the Floor (RFF) Velocity",
                    "description": "The rise from the floor test quantifies the time required for the subject to stand in an upright position with arms by sides, starting from the supine position with arms by sides.",
                    "timeFrame": "Baseline to Week 52"
                },
                {
                    "measure": "Observed Serum Concentration of Satralizumab at Specified Trough Timepoints Up To Week 104",
                    "timeFrame": "Up to Week 104"
                },
                {
                    "measure": "Apparent Clearance of Satralizumab",
                    "description": "Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.",
                    "timeFrame": "Up to Week 104"
                },
                {
                    "measure": "Apparent Volume of Distribution of Satralizumab",
                    "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.",
                    "timeFrame": "Up to Week 104"
                },
                {
                    "measure": "Area Under the Concentration-Time Curve of Satralizumab",
                    "description": "Area under the concentration-time curve from time zero to the last quantifiable concentration of Satralizumab in plasma.",
                    "timeFrame": "Up to Week 104"
                },
                {
                    "measure": "Anti-Drug Antibodies (ADAs) at Baseline and Incidence of ADAs During the Study",
                    "timeFrame": "Up to approximately 30 Months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Signed Informed Consent Form and Signed Assent Form when appropriate\n* Male at birth\n* A definitive diagnosis of DMD prior to screening based on documentation of clinical findings and prior confirmatory genetic testing using a clinical diagnostic genetic test.\n* Age \u2265 8 and \\< 16 years at the time of signing Informed Consent Form\n* Participants who are fracture-naive are additionally required to meet the following criteria:\n\n  * No history of prior low-trauma fractures before the baseline visit nor any radiological findings indicative of prevalent VF at the screening visit\n  * Be ambulatory, defined as able to walk independently without assistive devices. - Age \u2265 8 to \\< 12 years old at the time of screening\n* Participants with a prior history of low-trauma fractures are additionally required to meet the following criteria:\n\n  * Evidence of at least one prevalent vertebral compression fracture of Genant Grade 1 or higher (or radiographic signs of VF) or history of at least one low-trauma long-bone fracture (upper or lower extremity)\n  * Ambulatory (see above definition) if age \u2265 8 to \\< 12.\n  * Non-ambulatory if age \u2265 12 to \\<16\n* Daily oral corticosteroids\n\nKey Exclusion Criteria:\n\n* Major surgery (e.g. spinal surgery) within 3 months prior to Baseline or planned surgery or procedure that would interfere with the conduct of the study for any time during this study \u2022Presence of any clinically significant illness\n* Has serological evidence of current, chronic, or active human immunodeficiency virus, tuberculosis, hepatitis C, or hepatitis B infection \u2022Has a symptomatic infection (e.g. upper respiratory tract infection, pneumonia, pyelonephritis, meningitis) within 4 weeks prior to baseline\n* Body weight \\> 100 kg \u2022Treatment with prohibited therapies as defined by the protocol\n* Has received a live or live attenuated virus vaccine within 6 weeks of the Baseline visit or expects to receive a vaccination during the first 3 months after Baseline.\n* Has abnormal laboratory values considered clinically significant as defined by the protocol\n* Any medical condition that might interfere with the evaluation of lumbar spine BMD, such as severe scoliosis or spinal fusion.\n* Participant has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the investigator\n* Participant has an allergy or hypersensitivity to the study medication or to any of its constituents\n\nOther protocol defined inclusion and exclusion criteria may apply",
            "healthyVolunteers": false,
            "sex": "MALE",
            "genderBased": true,
            "genderDescription": "Male participants",
            "minimumAge": "8 Years",
            "maximumAge": "15 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Reference Study ID Number: BN45398 https://forpatients.roche.com/",
                    "role": "CONTACT",
                    "phone": "888-662-6728 (U.S.)",
                    "email": "global-roche-genentech-trials@gene.com"
                },
                {
                    "name": "Global Medical Information:",
                    "role": "CONTACT",
                    "email": "global-roche-genentech-trials@gene.com"
                }
            ],
            "locations": [
                {
                    "facility": "Children's Hospital of the King's Daughter",
                    "city": "Norfolk",
                    "state": "Virginia",
                    "zip": "23510",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Crystal Proud",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.84681,
                        "lon": -76.28522
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009136",
                    "term": "Muscular Dystrophies"
                },
                {
                    "id": "D000020388",
                    "term": "Muscular Dystrophy, Duchenne"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020966",
                    "term": "Muscular Disorders, Atrophic"
                },
                {
                    "id": "D000009135",
                    "term": "Muscular Diseases"
                },
                {
                    "id": "D000009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D000009468",
                    "term": "Neuromuscular Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000040181",
                    "term": "Genetic Diseases, X-Linked"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10293",
                    "name": "Inflammation",
                    "relevance": "LOW"
                },
                {
                    "id": "M26370",
                    "name": "Fractures, Bone",
                    "relevance": "LOW"
                },
                {
                    "id": "M12093",
                    "name": "Muscular Dystrophies",
                    "asFound": "Muscular Dystrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22185",
                    "name": "Muscular Dystrophy, Duchenne",
                    "asFound": "Duchenne Muscular Dystrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12092",
                    "name": "Muscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4589",
                    "name": "Atrophy",
                    "relevance": "LOW"
                },
                {
                    "id": "M22697",
                    "name": "Muscular Disorders, Atrophic",
                    "relevance": "LOW"
                },
                {
                    "id": "M12097",
                    "name": "Musculoskeletal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12411",
                    "name": "Neuromuscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M24877",
                    "name": "Genetic Diseases, X-Linked",
                    "relevance": "LOW"
                },
                {
                    "id": "T3963",
                    "name": "Muscular Dystrophy",
                    "asFound": "Muscular Dystrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "T698",
                    "name": "Becker Muscular Dystrophy",
                    "asFound": "Duchenne Muscular Dystrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1945",
                    "name": "Duchenne Muscular Dystrophy",
                    "asFound": "Duchenne Muscular Dystrophy",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC26",
                    "name": "Wounds and Injuries"
                },
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}